Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | QDPR | P09417 | 2/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11270086 | 0.94 | HDAC4 (0.37) | HTR2CPOLBESR2 | |
| SCHEMBL27008281 | 0.94 | ESR2 (0.35) | HTR2CPOLBESR2 | |
| SCHEMBL29125236 | 0.92 | KMO (0.39) | HTR2C | |
| SCHEMBL6568489 | 0.92 | KMO (0.39) | HTR2C | |
| SCHEMBL19435850 | 0.86 | SOS1 (0.34) | HTR2C | |
| SCHEMBL27969123 | 0.80 | — | — | |
| SCHEMBL19347097 | 0.78 | HTR2B (0.43) | QDPR | |
| SCHEMBL14672801 | 0.77 | JAK2 (0.32) | — | |
| SCHEMBL1716466 | 0.73 | HTR2C (0.32) | HTR2CPOLBESR2 | |
| SCHEMBL455528 | 0.73 | POLB (0.32) | POLBESR2QDPRNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | claimed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | claimed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | claimed |
| CN-116323557-A | Cyclobutylamide monoacylglycerol lipase modulators | 詹森药业有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-8324223-B2 | Substituted thieno [2,3-d] pyrimidines as HIV inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-12-04 | — | — | US | claimed |
| CN-101233135-B | Diaryl-purine, diaryl-azapurine and diaryl-deazapurine compounds as non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency virus | ARDEA BIOSCIENCES INC | 2012-10-03 | — | — | CN | claimed |
| US-20120225894-A1 | Substituted Thienol[2,3-d] pyrimidines as HIV Inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-09-06 | — | — | US | claimed |
| EP-1877411-B9 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES INC (US) | 2012-08-29 | — | — | EP | claimed |
| US-8211898-B2 | Substituted thieno[3,2-d]pyrimidines as HIV inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-07-03 | — | — | US | claimed |
| EP-1877411-B1 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES INC (US) | 2012-01-18 | — | — | EP | claimed |
| US-20090281124-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-11-12 | — | — | US | claimed |
| US-7595324-B2 | Substituted thieno[3,2-D]pyrimidines as HIV inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2009-09-29 | — | — | US | claimed |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | INTRABIOTICS PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | claimed |
| EP-1877411-A4 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES INC (US) | 2008-10-22 | — | — | EP | claimed |
| CN-101233135-A | Diaryl-purine, diaryl-azapurine and diaryl-deazapurine compounds as non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency virus | ARDEA BIOSCIENCES INC (US) | 2008-07-30 | — | — | CN | claimed |
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | US | claimed |
| EP-1877411-A2 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | Ardea Biosciences, Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| WO-2006122003-A2 | DIARYL-PURINE, AZAPURINES AND -DEAZAPURINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV | ARDEA BIOSCIENCES, INC. (US) | 2006-11-16 | — | — | WO | claimed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-5932583-A | PLANT SAFENING AGENT | NOVARTIS CROP PROTECTION, INC. (US) | 1999-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | CYCS, DCK, NSUN2 | HTR2C 3218/4885POLB 60/4885ESR2 4036/4885 |
| US-20120225894-A1 | Substituted Thienol[2,3-d] pyrimidines as HIV Inhibitors | TYMS, DUT, TYMP | HTR2C 2529/4885POLB 153/4885ESR2 2954/4885 |
| US-20090281124-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | CYCS, DCK, NSUN2 | HTR2C 3218/4885POLB 60/4885ESR2 4036/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | HTR2C 457/4885POLB 846/4885ESR2 2213/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | HTR2C 438/4885POLB 841/4885ESR2 2211/4885 |
| US-20090124802-A1 | Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv | PNP, TPMT, DUT | HTR2C 1778/4885POLB 322/4885ESR2 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.